Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2240 studies found for:    "cytogenetically normal acute myeloid leukemia" OR "Leukemia, Myeloid, Acute"
Show Display Options
Rank Status Study
21 Terminated IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Plerixafor;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
22 Recruiting Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Idarubicin
23 Terminated Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: decitabine iv;   Drug: volasertib iv infusion
24 Completed Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cytosar;   Drug: Arsenic trioxide
25 Completed A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
Condition: Leukemia, Myeloid, Acute
Intervention: Biological: CSL362
26 Recruiting A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: BI 836858
27 Not yet recruiting BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BAY1436032
28 Active, not recruiting Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: BI 6727 (d1 and 15);   Drug: Cytarabine
29 Recruiting BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 836858
30 Unknown  Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Cafusertib Hydrochloride
31 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
32 Recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
33 Active, not recruiting Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: placebo;   Drug: volasertib;   Drug: low dose cytarabine
34 Withdrawn A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Volasertib
35 Completed BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 2536
36 Recruiting PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Autologous Fecal Microbiota Transplantation
37 Completed Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
Condition: Acute Myeloblastic Leukaemia
Interventions: Drug: ARA-C;   Drug: Idarubicin;   Drug: Leucomax
38 Recruiting Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: JNJ-63709178
39 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
40 Unknown  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.